In this trial, meningioma patients harboring actionable targets are treated with small-molecule inhibitors, including neurofibromatosis-2 (NF2) mutations with GSK2256098, which is a focal adhesion kinase (FAK) inhibitor; SMO (ESCAT III) or PTCH1 mutations with vismodegib; CDK (ESCAT IV) or NF2 alterations with abemaciclib; and AKT (ESCAT III), PI3K, or PTEN mutations with capivasertib (Figure 1) [102,103,104]. The gene discussed is AKT1; the disease is meningioma.